Stockreport

Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers

TAKEDA PHARMA  (TKPYY) 
NASDAQ:AMEX Investor Relations: takeda.com/investors
PDF – Results from Phase 3 Studies Including TOURMALINE-MM3 Trial of NINLARO™ (ixazomib) as Post- Autologous Stem Cell Transplant Maintenance Therapy and ECH [Read more]